Loading
BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.94). IntOGen calls it a driver in 4 cohorts (0 activating, 4 loss-of-function), covering Colon Adenocarcinoma, Colorectal Adenocarcinoma.
In plain words · BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.
BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity.
No product in this corpus aims at BCL9L yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2002. Earliest sequence paper UniProt cites for the protein: Kubo et al, 2002, "Identification of a 500-kb region of common allelic loss in chromosome 11q23 in non-MYCN amplified type of neuroblastoma". Source.
Sources: HGNC HGNC:23688 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q86UU0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000186174 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.66, gastric cancer 0.52, melanoma 0.56, skin cancer 0.56 (GraphQL API, CC0)); IntOGen BCL9L (driver in 4 cohorts (Act 0, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1. Location: Nucleus (UniProt). Locus 11q23.3 (HGNC).
Query for this target: (TITLE:"BCL9L" OR ABSTRACT:"BCL9L" OR TITLE:"BCL9 like" OR ABSTRACT:"BCL9 like" OR TITLE:"B-cell CLL/lymphoma 9-like protein" OR ABSTRACT:"B-cell CLL/lymphoma 9-like protein" OR TITLE:"DLNB11" OR ABSTRACT:"DLNB11" OR TITLE:"B9L" OR ABSTRACT:"B9L" OR TITLE:"Bcl9-2" OR ABSTRACT:"Bcl9-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL9L, not a curated reading list.